SNYR earnings analysis
What we found in SNYR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Synergy CHC Corp. reported disappointing results for Q1 2026, with revenues declining to $5.49M, a decrease of approximately 33% from $8.17M in Q1 2025. The company's net loss widened to $2.57M, compared to a gain of $0.88M in the same quarter last year, reflecting deteriorating performance and challenges in their product sales.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Decline
- Revenue fell to $5,492,705 in Q1 2026, down from $8,170,534 in Q1 2025, representing a decrease of 33%.
- Widening Net Loss
- Net loss reached $2,568,899 in Q1 2026, a shift from a net income of $876,264 in Q1 2025.
- Gross Margin Decline
- Gross profit margin decreased to 72% in Q1 2026, down from 75% in Q1 2025.
- Increased Operating Expenses
- General and administrative expenses rose to $2,048,850 in Q1 2026, compared to $1,306,714 in Q1 2025.
- High Interest Expense
- Interest expense increased to $2,012,121 in Q1 2026 from $1,095,369 in Q1 2025.
- Cash Position Weakening
- Cash on hand decreased to $292,115 as of March 31, 2026, raising liquidity concerns.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Accumulated Deficit
- Accumulated deficit grew to $59,009,920 by Q1 2026, reflecting ongoing financial struggles.
- Liquidity Concerns
- The company reported a working capital deficit of $503,862, indicating potential liquidity issues.
- Decreasing Consumer Demand
- A notable decrease in online sales contributed to the revenue drop in Nutraceuticals, questioning future performance.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.35
- Gross margin
- 72%
- Segment
- Nutraceuticals: $4,824,763
- Segment
- Beverages: $667,942
- Segment
- License Revenue: $0
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · April 1, 2026
- Synergy CHC positions itself as an asset-light nutraceutical brand platform focused on two marquee brands (FOCUSfactor and Flat Tummy) and plans to accelerate FOCUSfactor RTD and geographic expansion. Financially the…
- 10-K · March 31, 2025
- The 2024 Form 10-K positions Synergy CHC around two core brands (FOCUSfactor and Flat Tummy) with an asset-light, retailer-focused growth strategy driven by SKU expansion, RTD pilots and international entry plans…
- 10-Q · December 6, 2024
- Synergy CHC Corp. reported Q3 2024 revenues of $7.13 million, down 34% from $10.81 million in Q3 2023 and year-to-date revenues of $24.56 million, down 17% year-on-year. The company reported net income of $783,593 this…
- 10-Q · November 14, 2019
- Synergy CHC reported quarter revenues of $7,364,546 (down from $9,190,377 a year ago) while recording net income of $107,864 for the three months and year-to-date net income of $1,893,613 versus a loss of $(493,296)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SNYR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever